von Hippel-Lindau syndrome
von Hippel Lindau

Contact us
 
Return to database


We were unfortunately unable to download the information for this disease from OMIM.



Prevalence of clinical parameters (%)







Add new symptom/sign to this disease

Select symptom from list or write it in the box
Pubmed id number as a reference Organ system affected
Number of patients in the reference Percent affected patients (Between 0 and 1, eg. 0.1 = 10%)
Please provide your name and contact information as a reference
Name Institute Phone number Email address


List of symptoms



Symptom/sign Organ system Percent affected Pubmed id Added on(yyyy-mm-dd) Edit/add reference
Cerebellar haemangioblastoma nervous 60 % 8929948 2011-12-07
Cancer multi 60 % 8929948 2012-01-24
Retinal angioma nervous 41 % 8929948 2011-12-07
Renal cell carcinoma urinary 25 % 8929948 2011-12-07
Kidney cysts urinary 24 % 8929948 2011-12-07
Pancreatic cysts digestive 16 % 8929948 2011-12-07
Spinal haemangioblastoma nervous 15 % 8929948 2011-12-07
Phaeochromocytoma circulatory 15 % 8929948 2011-12-07
Pancreatic carcinoma digestive 5 % 8929948 2011-12-07
Brainstem haemangioblastoma nervous 4 % 8929948 2011-12-07
Liver cysts digestive 2 % 8929948 2011-12-07



List of references:


A genetic register for von Hippel-Lindau disease.
I R Maddock, A Moran, E R Maher, M D Teare, A Norman, S J Payne, R Whitehouse, C Dodd, M Lavin, N Hartley, M Super, D G Evans,

A genetic register for von Hippel-Lindau disease was set up in the north west of England in 1990. Population statistics, clinical features, age at onset, and survival of 83 people affected with von Hippel-Lindau (VHL) disease were studied. In addition, the effectiveness of the screening programme used and the occurrence of central nervous system haemangioblastomas in the general population were examined. The diagnostic point prevalence of heterozygotes in the North Western Region was 1 center dot 18/100 000 (1/85 000) people, with an estimated birth incidence of 2 center dot 20/100 000 (1/45 500) live births. The mutation rate was estimated directly to be 1 center dot 4 x 10(-6)/gene/generation (1/714 200). The mean age at onset of first symptoms was 26 center dot 25 years, with cerebellar haemangioblastoma being the most common presenting manifestation (34 center dot 9% of cases). The mean age at diagnosis of VHL disease was 30 center dot 87 years. Overall, 50 patients (60 center dot 2%) developed a cerebellar haemangioblastoma, 34 (41 center dot 0%) a retinal angioma, 21 (25 center dot 3%) a renal cell carcinoma, 12 (14 center dot 5%) a spinal haemangioblastoma, and 12 (14 center dot 5%) a phaeochromocytoma. Mean age at diagnosis of renal cell carcinoma (38 center dot 9 years) was significantly higher than that for cerebellar haemangioblastoma (30 center dot 0 years) and retinal angioma (21.1 years). Mean age at death was 40 center dot 9 years with cerebellar haemangioblastoma being the most common cause (47 center dot 7% of deaths). A total of 65 VHL manifestations were diagnosed asymptomatically following appropriate clinical and radiological screening tests, and failure to detect manifestations of VHL disease in spite of appropriate screening occurred on only two occasions. The use of DNA linkage analysis and direct mutation testing reduced the personal risk of carrying the VHL gene to below 1% in 14 people. In addition to the 83 clinically affected subjects, three obligate carriers who were considered to be lesion free in spite of extensive screening tests were identified. Fourteen percent of all CNS haemangioblastomas on the regionally based Cancer Registry were found to occur as part of VHL disease, but investigations for VHL in apparently sporadic disease appeared to be limited.

Journal of medical genetics - Feb 1996